雅虎香港 搜尋

搜尋結果

1. portal.sina.com.hk › finance › finance-globenewswireFDA Grants Orphan Drug Designation to Biompharma’s ...

   portal.sina.com.hk › finance › finance-globenewswire

   • 網頁紀錄

   2024年5月8日 · Bi104 granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of Angelman syndrome (AS). Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) — BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the U.S ...

2. portal.sina.com.hk › finance › finance-globenewswireAcasti Pharma to Attend BIO International Convention 2024

   portal.sina.com.hk › finance › finance-globenewswire

   • 網頁紀錄

   2024年5月28日 · Acasti’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery.

3. 其他人也問了

   Did Ben Johnson take steroids?

   • Ben Johnson initially denied taking steroids during the Seoul Olympics in 1988. However, he later admitted taking them before a Canadian Government investigation committee in 1989. So what types of steroids was Ben Johnson using? Ben confessed to using two anabolic steroids, Dianabol and Winstrol, during his career as an Olympic athlete.

   Is Ben Johnson On Steroids? - Testosterone.org

   www.testosterone.org/ben-johnson-steroids/

   查看此問題的所有搜尋結果

   Who is Dr Ben Johnson?

   • Dr. Ben Johnson, MD is a cardiology specialist in Little Rock, AR and has over 52 years of experience in the medical field. He graduated from UNIVERSITY OF TEXAS MEDICAL SCHOOL AT SAN ANTONIO in 1970. He is affiliated with CHI St. Vincent Infirmary. His office is not accepting new patients.

   Dr. Ben Johnson, MD | Little Rock, AR | Healthgrades

   www.healthgrades.com/physician/dr-ben-johnson-xqtlg

   查看此問題的所有搜尋結果

   What happened to Ben Johnson?

   • This is disappointing, to say the least. Ben Johnson had the genetics and the inner drive to become one of the greatest Olympic athletes of all time. After he was found guilty of doping, he was stripped of his gold medals, and his reputation was in the toilet.

   Is Ben Johnson On Steroids? - Testosterone.org

   www.testosterone.org/ben-johnson-steroids/

   查看此問題的所有搜尋結果

   Is bi104 an orphan drug?

   • Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) — BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of Angelman syndrome (AS).

   FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbi…

   portal.sina.com.hk/finance/finance-globenewswire/globenewswire/2024/05/08/835576/fda-grants-orphan-drug-designation-to-biompharmas-bi104-a-microbiome-modifying-biologic-for-the-treatment-of-angelman-syndrome/

   查看此問題的所有搜尋結果

4. portal.sina.com.hk › finance › finance-prnewswire鼎優樂®（舒巴坦鈉-度洛巴坦鈉）獲中國國家藥監局批准上市 - ...

   portal.sina.com.hk › finance › finance-prnewswire

   • 網頁紀錄

   2024年5月20日 · 根據世衛組織，耐藥鮑曼不動桿菌對全球健康的威脅日益緊迫，是亟需新型抗生素的病原體. 中國國家藥品監督管理局（NMPA）的批准是基於全面的臨床數據，證明SUL-DUR對耐碳青霉烯類鮑曼-醋酸鈣不動桿菌復合體菌株具有良好的活性. 中國約有30萬例不動 ...

5. portal.sina.com.hk › finance › finance-globenewswireJohnson & Johnson submits application to the European ...

   portal.sina.com.hk › finance › finance-globenewswire

   • 網頁紀錄

   6 天前 · BEERSE, BELGIUM, May 31, 2024 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson & Johnson company, announced today the submission of an application for the extension of the RYBREVANT ® (amivantamab) marketing authorisation (line extension) to the European Medicines Agency (EMA).

6. portal.sina.com.hk › finance › finance-globenewswireCorcept Announces Primary Endpoint Met in Pivotal Phase 3 ...

   portal.sina.com.hk › finance › finance-globenewswire

   • 網頁紀錄

   2024年5月28日 · The company expects to submit its New Drug Application in the third quarter. “The data from GRACE make a compelling case for the use of relacorilant in patients with endogenous hypercortisolism.

7. portal.sina.com.hk › finance › finance-globenewswireONWARD® Medical Reports Q1 2024 Update and Year-to-Date ...

   portal.sina.com.hk › finance › finance-globenewswire

   • 網頁紀錄

   2024年5月23日 · Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT® (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer

8. portal.sina.com.hk › finance › finance-globenewswireKFSH&RC 被評為沙特阿拉伯和中東地區最具價值的醫療保健品牌 ...

   portal.sina.com.hk › finance › finance-globenewswire

   • 網頁紀錄

   2024年5月3日 · Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT® (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer